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Background/Aims: The aim of this study was to evaluate the 
estimated glomerular filtration rate (eGFR) during telbivudine 
(LdT) versus entecavir (ETV) treatment in chronic hepatitis 
B (CHB) patients with underlying comorbidities such as dia-
betes mellitus (DM), hypertension, and cirrhosis. Methods: 
From 2010 to 2012, 116 CHB patients treated with LdT and 
578 treated with ETV were compared in this real-practice co-
hort. The mean changes in eGFR (Modification of Diet in Re-
nal Disease [MDRD] formula) from baseline to months 6, 12, 
and 18 were analyzed using a linear mixed model. Results: 
In LdT-treated patients, the mean eGFR increased by 7.6% at 
month 18 compared with the eGFR at baseline (MDRD for-
mula in mL/min/1.73 m2). However, in ETV-treated patients, 
the mean eGFR decreased by 4.1% at month 18 compared 
with the eGFR at baseline. In the LdT-treated patients with 
DM, hypertension, cirrhosis or low eGFR <90 mL/min/1.73 
m2, the mean eGFR showed a steady improvement, whereas 
the mean eGFR was reduced in the same subgroups of ETV-
treated patients. Conclusions: The eGFR gradually increased 
over time during LdT treatment, especially in patients with 
mild abnormal eGFR at baseline, and in those with DM, hy-
pertension, and cirrhosis, whereas a reduction in eGFR was 
seen with ETV treatment. (Gut Liver 2015;9:776-783)
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INTRODUCTION
Hundreds of million people are chronic hepatitis B virus sur-
face antigen (HBsAg) carriers with serological evidence and 75% 
of chronic hepatitis B (CHB) reside in the Asia Pacific region.1 
Despite the availability of highly effective and safe vaccines for 
more than 20 years, hepatitis B virus (HBV) infection remains 
the most common worldwide cause of death from liver disease.2
With an expanded range of treatment options and a substan-
tial improvement in the understanding of predictors of response 
to therapy, the management of patients with CHB continues 
to evolve. Currently, there are five oral nucleos(t)ide analogues 
approved for the treatment of CHB, including three nucleoside 
analogues (lamivudine, telbivudine, and entecavir), and two 
nucleotide analogues (adefovir and tenofovir).3 Each of these 
agents showed the effective and profound suppression of viral 
replication, facilitating hepatitis B e antigen (HBeAg) serocon-
version, achieving alanine aminotransferase (ALT) normaliza-
tion, and improving liver fibrosis. Telbivudine (LdT) is a specific 
inhibitor of HBV polymerase which is more potent than adefo-
vir and which was also shown to be superior to lamivudine over 
2 years in the GLOBE study, the largest intent-to-treat analysis 
of long-term HBV nucleoside treatment to date.4,5
However, with higher numbers of patients now being treated 
for CHB, possible adverse events have gained more attention. 
One area of concern is renal function. CHB is itself important 
causes of renal disease. In addition to secondary glomerular dis-
ease which can be caused by the HBV, treatment of HBV can be 
potentially nephrotoxic. Adefovir and tenofovir are both acyclic 
nucleotide analogues structurally, which have been shown to be 
nephrotoxic.6 It has been shown that among a low percentage 
of human immunodeficiency virus infected patients receiving 
tenofovir, the estimated glomerular filtration rate (eGFR) de-
creases, as measured by increases in serum creatine.7
In contrast, recent analyses from clinical studies demonstrated 
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Lee S, et al: The Effect on eGFR of LdT and ETV  777
that long-term LdT treatment is associated with steady improve-
ment in renal function, including in-patients with pre-existing 
renal disease although the potential mechanisms are unclear.8 
As a view of entecavir (ETV) which is one of recommended an-
tiviral agents, there is no published study indicating this finding 
and it has been not known whether long-term treatment with 
ETV affects renal function. Additionally, renal function can 
be influenced by underlying disease including liver cirrhosis, 
hypertension, and diabetes mellitus (DM). Therefore, it is impor-
tant to decide the antiviral agents to protect the renal function 
for the patients who have the possibility of renal deterioration 
because of underlying disease. The present study aimed to com-
pare the efficacy and safety of LdT and ETV in patients who 
received therapy for 18 months according to underlying disease 
including liver cirrhosis, hypertension, and DM.
MATERIAL AND METHODS 
1. Patient enrollment 
From 2010 to 2012, 116 CHB patients treated with LdT and 
578 with ETV were compared in this real practice cohort. We 
included patients treated by LdT or ETV more than 18 months 
and their age was more than 20 years. Exclusion criteria were 
followings: co-infected with hepatitis C or human immunodefi-
ciency virus, patient who was pregnant or breastfeeding, patient 
treated by combination regimen in addition to LdT or ETV, a 
history of liver transplantation, chronic renal failure patients 
with hemodialysis or peritoneal dialysis, and patient who was 
enrolled in another clinical trial. One group was given LdT 600 
mg daily and other group was given ETV 0.5 mg daily. 
This study was performed in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki. This study was 
approved by the independent Institutional Review Board of Sev-
erance Hospital.
2. Serum assay
Analyses of liver function, renal function and creatine kinase 
level were performed at baseline and at months 6, 12, and 18 of 
LdT and ETV therapy. HBsAg, HBeAg, antibody to hepatitis B 
core antigen (anti-HBc), antibody to HBeAg (anti-HBe) and an-
tibody to HBsAg (anti-HBs) were quantified using radioimmu-
noassay (Abbott Laboratories, Abbott Park, IL, USA). HBV DNA 
was measured using the real-time polymerase chain reaction as-
say on a Cobas TaqMan 48 analyzer (Roche Molecular Systems, 
Branchburg, NJ, USA) with the lower detection limit of 20 IU/
mL. The mean change of eGFR from baseline to 6, 12, and 18 
months were analyzed according to the underlying disease in-
cluding liver cirrhosis, hypertension, and DM. The measurement 
of eGFR which was based on renal function was assessed using 
the Modification of Diet in Renal Disease (MDRD) formula for 
the calculation of eGFR.9 We investigated the change of eGFR 
for the 18 months of follow up. Hypertension was defined ac-
cording to by the seventh report of the Joint National Commit-
tee and DM was defined as according to the criteria of Ameri-
can Diabetes Association.10,11 They were followed up in our 
hospital for the treatment or clinical observation. Liver cirrhosis 
was diagnosed using clinical tools including blood test, imaging 
studies or biopsy. In addition, blood urea nitrogen (BUN) and 
creatine (Cr) level and other laboratory finding were collected.
3. Statistical analysis
Quantitative data were presented as mean±standard devia-
tion, categorical data were presented as counts and percentages, 
and HBV DNA levels were presented as log transformation. The 
primary endpoint was to estimate the change of eGFR in CHB 
patients treated by ETV and LdT, while secondary outcome was 
to investigate the change of eGFR in patients with DM, hyper-
tension, and liver cirrhosis treated by ETV and LdT. The mean 
eGFR change compared to baseline eGFR was defined as (eGFR 
at 18 months–baseline eGFR)/baseline eGFR. Mixed linear Mod-
el was used to compare eGFR of patients treated by between 
ETV and LdT, and chi-square or Fisher exact tests was used for 
categorical variables. Statistical analyses were performed using 
SAS version 9.1.3 (SAS, Cary, NC, USA). A two-sided p-value 
<0.05 was considered statistically significant.
RESULTS
1. Baseline characteristics
The mean age was 53 years in ETV group and 54 years in 
LdT. In the beginning of treatment, the underlying disease in-
cluding liver cirrhosis (50.9% vs 51.7%), hypertension (23.1% 
vs 28.4%), and DM (18.9% vs 19.8%) were found in ETV and 
LdT group, respectively. We investigated laboratory result in the 
beginning of treatment including HBV DNA level, ALT, alanine 
aspartate aminotransferase (AST), calcium, phosphate, BUN, Cr, 
eGFR, and total bilirubin. Any result did not show the mean-
ingful difference between two groups. In ETV group, HBeAg 
positive were 300 (51.6%) and in LdT group were 55 (44.7%) 
(p>0.05). The mean ALT value was 85.0 IU/L and 80.3 in ETV 
and LdT group, respectively (Table 1). The baseline of mean 
serum glucose level in patients with DM was 138.1±72.3 mg/dL 
versus 132.1±77.4 mg/dL (p=0.717) and the mean HbA1c was 
7.3%±1.7% versus 7.4%±1.4% in ETV and LdT group (p=0.940), 
respectively. The mean systolic blood pressure in patients with 
hypertension was 144.2±6.3 mm Hg versus 144.4±63.5 mm Hg 
(p=0.852) and diastolic blood pressure was 85.6±7.6 mm Hg 
versus 85.0±8.7 mm Hg (p=0.655) in ETV and LdT group.
2. Viral response after 18 months treatment
For 18 months treatment, HBV DNA level was reduced from 
5.6 log10 IU/mL to 1.5 log10 IU/mL in ETV group, but from 5.7 
log10 IU/mL to 2.5 log10 IU/mL in LdT group. The reduction HBV 
level compared to baseline HBV DNA level was shown that 
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65.1% was in ETV and 48.4% in LdT (p=0.004).
3. The mean eGFR change at months 6, 12, and 18 in entire 
cohort 
In 116 LdT-treated patients, the mean eGFR changes from 
baseline to months 6, 12, and 18 showed an improvement of 
91.4, 91.6, and 94.7 compared to 89.9 of the baseline eGFR 
level (MDRD formula in mL/min/1.73 m2). However, in 578 
ETV-treated patients, the mean eGFR changes from baseline to 
months 6, 12, and 18 showed an aggravation of 85.5, 85.4, and 
84.6 compared to 89.1 of the baseline eGFR level (MDRD for-
mula in mL/min/1.73 m2). They showed the significant different 
tendency in the change of eGFR level during the antiviral treat-
ment (p=0.001 analyzed by linear mixed model) (Table 2). In 
the mean eGFR change/baseline eGFR (%) showed -4.1%±7.6% 
in ETV group, but the increase of 7.6±17.4 was noticed in LdT 
group (Fig. 1).
4. The mean eGFR change at months 6, 12, and 18 according 
to the baseline eGFR
In subgroup analysis of LdT-treated patients according to the 
baseline eGFR, the mean eGFR changes from baseline to months 
6, 12, and 18 showed different outcomes. 
In LdT-treated patients with the low mean baseline eGFR 
(<90 mL/min/1.73 m2) showed a significant improvement of 
81.0, 81.6, and 86.3 at the time of months 6, 12, and 18 com-
pared to 76.1 of the baseline eGFR level (MDRD formula in mL/
min/1.73 m2). However, in LdT-treated patients with the normal 
mean baseline eGFR showed a slight increase through months 
6, 12, and 18. In ETV-treated patients, the mean eGFR changes 
to months 6, 12, and 18 regardless with low and high baseline 
showed a eGFR reduction of 75.7, 76.1, 75.1, and 96.8, 96.1, 
Table 1. Demographic and Other Baseline Characteristics of Patients 
Treated by Entecavir and Telbivudine
Characteristic ETV (n=578) LdT (n=116)
Age, yr 53.6±10.9 54.8±11.3
Male sex 402 (69.2) 63 (54.3)
Underlying disease
   Liver cirrhosis 296 (51.2) 60 (51.7)
   Hypertension 134 (23.1) 33 (28.4)
   Diabetes mellitus 110 (18.9) 23 (19.8)
HBV DNA, IU/mL 2.2×107±4.4×107 2.1×107±4.5×107
HBeAg positive/negative 300 (51.6)/281 (48.4) 55 (44.7)/61 (52.6)
ALT, IU/L 85.0±65.8 80.3±78.8
AST, IU/L 113.4±270.3 67.8±41.4
Calcium 8.7±0.5 8.8±0.5
Phosphate 3.5±0.6 3.4±0.5
Blood urea nitrogen, mg/dL 14.6±8.3 13.3±4.3
Creatinine, mg/dL 1.1±0.7 1.0±0.3
eGFR, mL/min/1.73 m2 89.1±19.9 89±18.6
Continuous values are expressed as mean±SD and other values are 
number (%).
ETV, entecavir; LdT, telbivudine; HBV, hepatitis B virus; HBeAg, 
hepatitis B e antigen; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; eGFR, estimated glomerular filtration rate (Modifi-
cation of Diet in Renal Disease formula in mL/min/1.73 m2).
Table 2. The Mean Estimated Glomerular Filtration Rate Change at Months 6, 12, and 18
Entire cohort eGFR <90 mL/min/1.73 m2 eGFR ≥90 mL/min/1.73 m2
ETV (n=578) LdT (n=116) ETV (n=310) LdT (n=61) ETV (n=271) LdT (n=55)
Baseline 89.1±19.9 89.9±18.6 75.4±14.3 76.1±13.2 104.7±12.7 103.3±12.1
Months 6 85.5±19.7 91.4±18.6 75.7±17.4 81.0±15.7 96.8±15.8 101.7±15.9
Months 12 85.4±20.2 91.6±20.1 76.1±18.6 81.6±16.5 96.1±16.3 102.8±17.7
Months 18 84.6±20.3 94.7±19.1 75.1±19.6 86.3±19.2 95.4±15.0 104±14.2
p-value <0.001 <0.001 <0.001
Values are expressed as mean±SD. The change of eGFR between two groups was analyzed by linear mixed model. 
eGFR, estimated glomerular filtration rate (Modification of Diet in Renal Disease formula in mL/min/1.73 m2); ETV, entecavir; LdT, telbivudine.
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Fig. 1. Analysis for mean change in estimated glomerular filtration 
rate (eGFR) from baseline to month 18 of therapy by underlying 
disease. The mean eGFR change compared with baseline eGFR was 
defined as (eGFR at 18 months–baseline eGFR)/baseline eGFR.
MDRD, Modification of Diet in Renal Disease; LdT, telbivudine; ETV, 
entecavir.
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95.4, respectively (p<0.001 analyzed by linear mixed model) 
(Table 2, Fig. 2).
In the subgroup of low eGFR, the mean eGFR change/base-
line eGFR (%) was increased to 13.4% after 18 months LdT use, 
but the reduction of 0.6% was noticed after 18 months ETV use. 
In the subgroup of high eGFR, the mean eGFR change/baseline 
eGFR (%) was reduced to 8.0% after 18 months ETV use, but the 
significant change was not found after 18 months LdT use (Fig. 1). 
5. The mean eGFR change at months 6, 12, 18 according 
to the presence of DM
In subgroup analysis of LdT-treated patients with DM, the 
mean eGFR changes from baseline to months 6, 12, and 18 
showed a different outcomes. In LdT-treated patients with DM 
showed a significant improvement of 89.0, 88.0, and 90.0 at 
the time of months 6, 12, and 18 compared to 87.0 of the base-
line eGFR level (MDRD formula in mL/min/1.73 m2). In ETV-
treated patients, the mean eGFR changes to months 6, 12, and 
18 showed a significant aggravation of 79.5, 79.0, and 78.5 in 
patients with DM compared to 85.5 of the baseline eGFR level 
(MDRD formula in mL/min/1.73 m2) (p=0.001 analyzed by 
linear mixed model) (Table 3, Fig. 3). In the subgroup of DM, 
the mean eGFR change for 18 months/baseline eGFR (%) was 
increased to 2.5% after 18 months LdT use, but the reduction of 
6.0% was noticed after 18 months ETV use (Fig. 1). 
6. The mean eGFR change at months 6, 12, 18 according 
to the presence of hypertension
In subgroup analysis of LdT-treated patients with hyperten-
sion, the mean eGFR changes from baseline to months 6, 12, 
and 18 showed a different outcome. In LdT-treated patients with 
hypertension showed a significant improvement of 86.0, 86.4, 
and 86.6 at the time of months 6, 12, and 18 compared to 84.2 
of the baseline eGFR level (MDRD formula in mL/min/1.73 m2) 
(Table 3, Fig. 3). In ETV-treated patients, the mean eGFR chang-
es to months 6, 12, and 18 showed a significant aggravation of 
74.9, 75.7, and 74.8 in patients with hypertension compare to 
80.8 of the baseline eGFR level (MDRD formula in mL/min/1.73 
m2) (p=0.020 analyzed by linear mixed model) (Table 3). In the 
subgroup of hypertension, the mean eGFR change/baseline 
eGFR (%) was increased to 4.2% after 18 months LdT use, but the 
reduction of 5.4% was noticed after 18 months ETV use (Fig. 1). 
7. The mean eGFR change at months 6, 12, 18 according 
to the presence of liver cirrhosis
In subgroup analysis of LdT-treated patients with liver cir-
rhosis, the mean eGFR changes from baseline to months 6, 12, 
and 18 showed a different outcome. In LdT-treated patients with 
liver cirrhosis showed a significant improvement of 93.1, 93.6, 
and 97.5 at the time of months 6, 12, and 18 compared to 91.0 
of the baseline eGFR level (MDRD formula in mL/min/1.73 m2) 
(Table 3, Fig. 3). In ETV-treated patients, the mean eGFR chang-
es to months 6, 12, and 18 showed a significant aggravation of 
84.4, 83.8, and 83.4 in patients with liver cirrhosis compared to 
88.6 of the baseline eGFR level (MDRD formula in mL/min/1.73 
m2) (p=0.001 analyzed by linear mixed model) (Table 3, Fig. 3). 
In the subgroup of liver cirrhosis, the mean eGFR change/base-
line eGFR (%) was increased to 8.4% after 18 months LdT use, 
but the reduction of 4.8% was noticed after 18 months ETV use 
(Fig. 1). 
In liver cirrhosis with Child-Pugh class A, LdT treatment 
showed the increase of eGFR level of 91.5, 93.1, 93.1, and 
97.5 from baseline to months 6, 12, and 18 while ETV treat-
ment showed the decrease of eGFR level of 90.4, 86.1, 86.4, 
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Fig. 2. Evolution of renal function after 18 months of treatment. The black and gray bars indicate estimated glomerular filtration rate (eGFR; mL/
min/1.73 m2) with telbivudine (LdT) and entecavir (ETV) treatment, respectively. (A) Patients with baseline eGFR ≤90 mL/min/1.73 m2 showed a 
rise in eGFR with LdT treatment, whereas eGFR declined with ETV therapy. (B) Patients with baseline eGFR >90 mL/min/1.73 m2 showed slight 
increases in eGFR with LdT treatment, whereas eGFR in ETV recipients declined.
MDRD, Modification of Diet in Renal Disease.
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and 85.6 (p<0.001 analyzed by linear mixed model). In liver 
cirrhosis with Child-Pugh class B or C, LdT treatment showed 
the increase of eGFR level of 87.7, 96.6, 93.3, and 97.1 from 
baseline to months 6, 12, and 18 while ETV treatment showed 
the decrease of eGFR level of 82.2, 78.4, 74.4, and 75.3 (p=0.018 
analyzed by linear mixed model). 
DISCUSSION
Although oral antiviral agents are the first line treatment of 
CHB and generally well tolerated, some patients have undergone 
the difficult to use these necessary medication because of ad-
verse events. For example, some antiviral agents can potentially 
cause adverse events including myopathy, nephropathy, neu-
ropathy, and lactic acidosis. Especially, the effects on muscles 
including myopathy and creatine kinase elevations have been 
described with clevudine and LdT use.12,13 Adefovir is related 
with dose-dependent nephropathy, predominantly affecting 
the proximal renal tubules.14 Increased risk of lactic acidosis 
has also been described for those with impaired liver and renal 
function taking ETV.15 Loss of bone mineral density and hy-
pophosphatemia has been described with the use of nucleotide 
Table 3. Subanalysis for the Patients with Diabetes Mellitus, Hypertension, and Liver Cirrhosis: Estimated Glomerular Filtration Rate from Baseline 
to Months 6, 12, and 18 of Entecavir and Telbivudine
Diabetes mellitus Hypertension Liver cirrhosis
ETV (n=110) LdT (n=23) ETV (n=134) LdT (n=33) ETV (n=296) LdT (n=60)
Baseline 85.5±26.6 87.0±25.5 80.8±25.2 84.2±22.8 88.6±20.2 91.0±14.5
Months 6 79.5±26.0 89.0±21.7 74.9±22.5 86.0±20.4 84.4±20.1 93.1±13.5
Months 12 79.0±24.5 88.0±24.9 75.7±25.1 86.4±23.0 83.8±20.4 93.6±14.9
Months 18 78.5±25.6 90.0±26.9 74.8±25.4 86.6±23.7 83.4±21.3 97.5±16.0
p-value 0.001 0.020 0.001
Values are expressed as mean±SD. The change of estimated glomerular filtration rate between two groups was analyzed by linear mixed model. 
ETV, entecavir; LdT, telbivudine.
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Fig. 3. Evolution of renal function according to underlying disease. 
The black and gray bars indicate estimated glomerular filtration rate 
(eGFR; mL/min/1.73 m2) with telbivudine (LdT) and entecavir (ETV) 
treatment, respectively. The eGFR rose in LdT-treated patients but de-
creased in patients given ETV. (A) Diabetes mellitus. (B) Hypertension. 
(C) Cirrhosis.
MDRD, Modification of Diet in Renal Disease.
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analogues.16 However, not all extra-hepatic effects are seriously 
harmful. 
Clinicians take a profound consideration when they adjust the 
dose of antiviral agents according to the degree of renal impair-
ment because all of the approved antiviral agents undergo renal 
clearance predominantly in their unchanged forms and some 
nucleotide analogs are also associated with dose-dependent 
nephrotoxicity.17 Especially at adefovir administration with 
doses of 10 and 30 mg, the efficacy of both groups was similar 
but renal adverse effects were more common with 30 mg. In 
a study of 80 patients treated with ETV compared to the same 
number treated with tenofovir, 13.8% of patients treated with 
ETV showed serum creatine increase ≥0.5 mg/dL and 8.7% of 
patients showed eGFR <60 mL/min.18
In the REVEAL study, the risk of developing cirrhosis and 
hepatocellular carcinoma was directly proportional to serum 
HBV DNA levels.19 ETV has been shown to be highly effective 
at suppressing HBV DNA replication to undetectable levels and 
normalizing ALT.20,21 Of note is the very low resistance rate 
(1.2%) observed in nucleoside-naive HBeAg-negative patients 
treated with ETV for up to 5 years. The effective and prolonged 
suppression of HBV DNA using ETV, which reduces the risk of 
cirrhosis and HCC, is the primary treatment goal.22,23
ETV showed a safety and tolerability in long-term cohort 
study20,24,25 and the fatal renal toxicity has not reported in the 
real practice. However, the recommendation was suggested for 
the renal impairment: (1) Clcr 30 to 49 mL/min: 50% of usual 
dose daily or normal dose every 48 hours; (2) Clcr 10 to 29 mL/
min: 30% of usual dose daily or normal dose every 72 hours; (3) 
Clcr <10 mL/min (including hemodialysis and peritoneal dialy-
sis): 10% of usual dose daily or the normal dose every 7 days.
In contrast, recent evidences have suggested a potential re-
nal beneficial effect with the use of LdT. LdT is one of strong 
potency nucleoside which was established the superiority over 
lamivudine in HBeAg-positive and HBeAg-negative patients 
in GLOBE trial although the resistance rate at 2 years for LdT 
is 11%.26-29 Several real-life studies have also shown potential 
renal improvements that were observed in a broad spectrum of 
CHB patients. In a randomized double-blinded trial of LdT in 
decompensated CHB, there was a reduction in serum creatine 
and increase in eGFR observed after 52 weeks of LdT treatment 
compared to lamivudine.30 This improvement was more marked 
for those age >50 years and for those with reduced GFR (60 to 
90 mL/min) at baseline. Of the patients with reduced GFR at 
baseline (60 to 90 mL/min), 72.3% moved to GFR >90 mL/min 
after 104 weeks of LdT treatment. 
There are limited direct head-to-head trials comparing the 
different antiviral agents. Although the previous studies com-
pared the efficacy of antiviral drugs, there are many limitations 
including the small size of patient groups and a heterogeneous 
baseline which can influence the renal dysfunction. In global 
trials, long-term LdT was associated with a sustained improve-
ment of renal function.8 However, it is still unclear in which 
specific population LdT is associated with the eGFR increase. 
Hence, we designed this cohort study to assess their efficacy 
and to verify the change of eGFR according to the underlying 
disease.
From our analysis, LdT improves eGFR after 18 months 
of treatment while ETV reduced the eGFR. Further subgroup 
analysis found that the improvement in renal function becomes 
apparent including patients with DM, hypertension, and cirrho-
sis, but the results of a predominant improvement in the first 6 
months and steady improvement during the remained 1 year. In 
the LdT-treated patients with DM, hypertension, cirrhosis or low 
eGFR of <90 mL/min/1.73 m2, the mean eGFR changes from 
baseline to months 6, 12, and 18 showed a steady improvement. 
Tsai et al.31 reported LdT was associated with eGFR improve-
ment, especially in patients with renal insufficiency. They in-
sisted there were significantly more patients with eGFR category 
improvement in the LdT groups at year 1, but there was no sig-
nificant improvement at year 2. Subgroup analysis of the mean 
eGFR change showed that both LdT treated with worse baseline 
eGFR (<90 mL/min/1.73 m2) had better eGFR improvement. 
Simultaneously, in treated by LdT of 271 CHB patients and by 
ETV of 310 CHB patients with a ≤90 mL/min/1.73 m2 of eGFR, 
the change in eGFR was 13.4% and -0.6%, respectively. In our 
comparison between LdT (n=55) and ETV (n=61) with a >90 
mL/min/1.73 m2 of eGFR, a higher decline from baseline was 
noted in the ETV group while in the LdT group increased with 
mild improvement (-8.0% vs 1.3%, respectively). Therefore, LdT 
is thought not to increase additionally the eGFR in patients with 
>90 mL/min/1.73 m2 of eGFR.
Special attention should be given to patients with a history of 
pre-existing renal insufficiency or other renal disease risks from 
comorbidities, because they are at increased risk of developing 
changes in renal function during prolonged CHB therapy. The 
major clinical relevance of accurate eGFR monitoring in DM 
patients has been further confirmed by recent evidence that low 
GFR was a strong risk factor for the prognosis related with vas-
cular disease and the regular checkup of eGFR was recommend-
ed in type 2 DM.32,33 In our study, LdT also showed significant 
improvement of eGFR in the group with DM. In DM with CHB 
patients, GFR was increased in LdT compared to ETV. Those 
taking LdT (n=23) and ETV (n=110) had a 2.5% and -6.0% GFR 
change, respectively. 
Hypertension is commonly present in patients with chronic 
kidney disease and the prevalence of hypertension varied in-
versely with GFR.34,35 In our study, LdT also showed significant 
improvement of eGFR in patients with hypertension. The 4.2% 
increase of eGFR compared to the baseline eGFR was found at 
months 18. However, in patients treated by ETV in the group 
with hypertension, 5.4% of eGFR was reduced compared to the 
baseline eGFR. 
Renal dysfunction is a common complication of cirrhosis and 
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confers a poor prognosis.36 Renal dysfunction occurs in 20% of 
patients with cirrhosis admitted to hospital, often linked with 
other complications of cirrhosis such as variceal bleeding and 
spontaneous bacterial peritonitis.37 In a systematic review of 118 
studies, the presence of renal dysfunction was a powerful pre-
dictor of death in decompensated cirrhosis.38 In our study, LdT 
also showed significant improvement of eGFR in the group with 
liver cirrhosis. The 8.4% of increase compared to the baseline 
eGFR was found. However, in patients treated by ETV in the 
group with liver cirrhosis, 4.8% of eGFR was reduced compared 
to the baseline eGFR. In further stratified by Child-Pugh class, 
eGFR in patients with Child-Pugh class B or C as well as Child-
Pugh class A showed the improvement. In the point that renal 
function is one of important prognostic factors for decompen-
sated liver cirrhosis, this phenomenon was a noticeable finding 
to make a plan for the treatment of CHB with liver cirrhosis. 
Serum creatine is one of three variables comprising the model 
for end-stage liver disease score which is widely used in pre-
dicting short term mortality in allocating priority for orthotopic 
liver transplantation.39 Although eGFR was changed through 18 
months, Cr has not been changed significantly compared to the 
baseline. It might be associated with the baseline Cr in patients 
were not abnormally low. It should be validated in more ex-
tended population with abnormal Cr and eGFR. 
We have some limitation in this report. First, it is a retrospec-
tive study. Second, we described the result that LdT increased 
the eGFR without any pathophysiologic theory. Although LdT 
treatment can affect angiotensin converting enzyme that can 
control renin-angiotensin aldosterone regulatory system in 
previous report,40 further investigations were required for this 
phenomenon under the pharmaco-pathophysiology.
In conclusion, GFR measurements may help in identifying 
subjects at risk of progression even before the onset of ne-
phropathy. The eGFR has been gradually increased over time 
during LdT treatment especially in patients with abnormal eGFR 
at baseline, DM, hypertension, and liver cirrhosis while the 
reduction of eGFR was seen with ETV treatment. The safety of 
nucleos(t)ide should be considered importantly because it will 
require long-term treatment and influence renal function. The 
further studies were required for the investigation of pathophys-
iology of LdT therapy to increase eGFR. 
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